A chemometrical approach to optimization and validation of an HPLC assay for rizatriptan and its impurities in tablets

Analytical Letters

Volumn 40, Issue 12, 2007, Pages 2301-2316

  Jocic B ^a   Zecevic M ^a   Zivanovic Lj ^a   Licanski A ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Dosage form; Impurities; Method validation; Rizatriptan benzoate; RP HPLC

Indexed keywords

EID: 35648972204     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032710701575959     Document Type: Article

References (31)

1. Ahuja, S. 1998. Impurities Evaluation of Pharmaceuticals; Marcel Dekker, Inc.: New York.
2. Altinoz, S., Ucar, G., and Yildiz, E. 2002. Determination of rizatriptan in its tablet dosage forms by UV spectrophotometric and spectrofluorimetric methods. Anal. Lett., 35: 2471-2485.
3. Araujo, P. 2000. A new high performance liquid chromatography multifactor methodology for systematic and simultaneous optimization of the gradient solvent system and the instrumental/experimental variables. Trends Anal. Chem., 19: 524-529.
4. Barrish, A., Olah, T.V., Gatto, G.J., Dobrinska, M.R., and Gilbert, J.D. 1996. The use of stable isotope labeling and liquid chromatography/tandem mass spectrometry techniques to study the pharmacokinetics and bioavailability of the antimigraine drug, MK-0462 in dogs. Rapid Commun. Mass Spectrom., 10: 1033-1037.
5. Chen, J., Glancy, K., Chen, X., and Alasandro, M. 2001. Investigation of pharmaceutical high-performance liquid chromatography assay bias using experimental design. J. Chromatogr. A, 917: 63-73.
6. Chen, J., Jiang, X.G., Jiang, W.M., Mei, N., Gao, X.L., and Zhang, Q. 2004. Liquid chromatographic method for the determination of rizatriptan in human plasma. J. Chromatogr. B, 805: 169-173.
7. Chen, J., Jiang, X.G., Jiang, W.M., Gao, X.L., and Mei, N. 2005. Intranasal absorption of rizatriptan - in vivo pharmacokinetics and bioavailability study in humans. Pharmazie, 60: 39-41.
8. Ficarra, R., Calabro, M.L., Cutroneo, P., Tommasini, S., Melardi, S., Semreen, M., Furlanetto, S., Ficarra, P., and Altavilla, G. 2000. Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design. J. Pharm. Biomed. Anal., 29: 1097-1103.
9. Ficarra, R., Ficarra, P., Tommasini, S., Melardi, S., Calabro, M.L., Furlanetto, S., and Semreen, M. 2000. Validation of a LC method for the analysis of zafirlukast in a pharmaceutical formulation. J. Pharm. Biomed. Anal., 23: 169-174.
10. Gennaro, M.C., Marengo, E., Gianotti, V., and Angioi, S. 2002. Simultaneous reversed-phase high-performance liquid chromatographic separation of mono-, di- and trichloroanilines through a gradient elution optimized by experimental design. J. Chromatogr. A, 945: 287-292.
11. Gori, S., Morelli, N., Bellini, G., Bonanni, E., Manca, L., Orlandi, G., Iudice, A., and Murri, L. 2005. Rizatriptan does not change cerebral blood flow velocity during migraine attacks. Brain Res. Bull., 65: 297-300.
12. Hund, E., Vander, Y., Heyden, M.H., Massart, D.L., and Smeyers-Verbeke, J. 2000. Robustness testing of a reversed-phase high-performance liquid chromatographic assay: comparison of fractional and asymmetrical factorial designs. J. Chromatogr. A, 874: 167-185.
13. ICH Q3A(R) 2000. Draft revised guidance on impurities in new drug substances. Fed. Regist., 65: 45085-45090.
14. ICH Q3B(R) 2000. Draft revised guidance on impurities in new drug products. Fed. Regist., 65: 44791-44797.
15. Jančić, B., Medenica, M., Ivanović, D., Malenović, A., and Marković, S. 2005. Microemulsion liquid chromatographic method for characterization of fosinopril sodium and fosinoprilat separation with chemometrical support. Anal. Bioanal. Chem., 383: 687-694.
16. Lee, Y., Conroy, J.A., Stepanavage, M.E., Mandel, C.M., Somers, G., McLoughlin, D.A., Olah, T.V., De Smet, M., and Rogers, J.D. 1999. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. J. Clin. Pharmacol., 47: 373-378.
17. Lundstedt, T., Seifert, E., Abramo, L., Thelin, B., Nystrom, A., Pettersen, J., and Bergman, R. 1998. Experimental design and optimization. Chemom. Intell. Lab. Syst., 42: 3-40.
18. Mahuzie, P., Clark, B.J., Crumpton, A.J., and Altria, K.D. 2001. Quantitative microemulsion electrokinetic capillary chromatography analysis of formulated drug products. J. Sep. Sci., 24: 784-788.
19. McLoughlin, D.A., Olah, T.V., Ellis, J.D., Gilbert, J.D., and Halpin, R.A. 1996. Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography - atmospheric pressure chemical ionization mass spectrometry. J Chromatogr. A, 726: 115-124.
20. Musson, D.G., Birk, K.L., Panebianco, D.L., Gagliano, K.D., Rogers, J.D., and Goldberg, M.R. 2001. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int. J. Clin. Pharmacol. Ther., 39: 447-452.
21. Nowak, M. and Seubert, A. 1999. Application of experimental design for the characterisation of a novel elution system for high-capacity anion chromatography with suppressed conductivity detection. J. Chromatogr. A, 855: 91-109.
22. Oldman, A.D., Smith, L.A., McQuay, H.S., and Moore, R.A. 2002. Pharmacological treatments for acute migraine: quantitative systematic review. Pain, 97: 247-257.
23. Orwa, J.A., Vandenbempt, K., Depuydt, S., Roets, E., and Hoogmartens, J. 1999. Liquid chromatography method for separation of clindamycin from related substances. J. Pharm. Biomed. Anal., 20: 745-752.
24. Ragonese, R., Mulholland, M., and Kalman, J. 2000. Full and fractionated experimental designs for robustness testing in the high-performance liquid chromatographic analysis of codeine phosphate, pseudoephedrine hydrochloride and chlorpheniramine maleate in a pharmaceutical preparation. J. Chromatogr. A, 870: 45-51.
25. Rao, B.M., Sangaraju, S., Srinivasu, M.K., Madhavan, P., Devi, M.L., and Kumar, P.R. 2006. Development and validation of a specific stability indicating high performance liquid chromatographic method for rizatriptan benzoate. J. Pharm. Biomed. Anal., 41: 1146-1151.
26. Vander Heyden, Y., Nijhuis, A., Smeyers-Verbeke, J., Vandeginste, B.G.M., and Massart, D.L. 2001. Guidance for robustness: ruggedness tests in method validation. J. Pharm. Biomed. Anal., 24: 723-753.
27. 1D receptor agonist rizatriptan benzoate and its potential process impurities. J. Liq. Chromatogr. Related Technol., 21: 1649-1670.
28. Vishwanathan, K., Bartlett, M.G., and Stewart, J.T. 2000. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom., 14: 168-172.
29. Williamson, D.J., Shepheard, S.L., Hill, R.G., and Hargreaves, R.J. 1997. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilatation and extravasation. Eur. J. Pharmacol., 328: 61-64.
30. Ye, C., Liu, J., Ren, F., and Okafo, N. 2000. Design of experiment and data analysis by JMP® (SAS institute) in analytical method validation. J. Pharm. Biomed. Anal., 23: 581-589.
31. Zeaiter, M., Roger, J.M., Bellon-Maurel, V., and Rutledge, D.N. 2004. Robustness of models developed by multivariate calibration. Part I: The assessment of robustness. Trends Anal. Chem., 23: 157-170.